23andMe’s Anne Wojcicki moves to reopen auction   with support from a Fortune 500 company

(Corrects paragraph 3 to say 23andMe filed for bankruptcy in March, not April)

The founder of 23andMe, Anne Wojcicki, has asked a U.S. judge to reopen an auction for the genetic testing company, saying she has the support of a Fortune 500 company with a current market capitalization of more than $400 billion.

Wojcicki did not name the Fortune 500 company in court filings.

South San Francisco, California-based 23andMe filed for bankruptcy in March, seeking to sell its business at auction after a decline in consumer demand and a 2023 data breach that exposed sensitive genetic and personal information of millions of customers.

Last month, Regeneron Pharmaceuticals agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and TTAM Research Institute, which was founded by Wojcicki and describes itself as a California non-profit public benefit corporation.

In a filing dated May 31, Wojcicki claimed that 23andMe’s debtors had attempted to tilt the sales process away from TTAM and in favor of Regeneron.

TTAM and Wojcicki said in the filing that 23andMe’s financial and legal advisers unfairly capped their maximum bid at $250 million due to misplaced concerns about TTAM’s “financial wherewithal”. The plaintiffs said the auction was prematurely concluded before they had the opportunity to submit a bid that would have exceeded $280 million.

The company’s debtors said the auction results came after an extensive and careful consideration by a four-member special committee of independent directors, according to the filing.

According to another filing, 23andMe is seeking court approval to let Wojcicki and Regeneron submit final proposals by June 12. 23andMe is also seeking a $10 million breakup fee for Regeneron if Wojcicki’s bid is ultimately accepted.

Regeneron said it does not comment on the ongoing proceeding and aims to close the acquisition as intended.

Lawyers for 23andMe’s debtors and TTAM parties did not immediately respond to emails seeking comment.

—Urvi Dugar, Reuters

https://www.fastcompany.com/91344281/23andmes-anne-wojcicki-moves-reopen-auction-support-fortune-500-company?partner=rss&utm_source=rss&utm_medium=feed&utm_campaign=rss+fastcompany&utm_content=rss

Établi 3mo | 2 juin 2025, 14:40:03


Connectez-vous pour ajouter un commentaire

Autres messages de ce groupe

Palantir is mapping government data. What it means for governance

When the U.S. government signs contracts with private technology companies, the fine print rarely reaches the public. Palantir Technologies, however, has at

30 août 2025, 09:10:09 | Fast company - tech
‘The New York Times’ paywalled the Mini Crossword and the internet is in shambles

Bad news for morning routines everywhere: The New York Times has put its Mini Crossword behind a paywall.

On Tuesday, instead of their usual puzzle, players were met with a paywall. The

29 août 2025, 19:20:05 | Fast company - tech
Chinese tech giant Alibaba aims to fill Nvidia void with its new AI chip

China’s Alibaba has developed a new chip that is more versatile than its older chips and is meant to serve a broader range of

29 août 2025, 16:50:06 | Fast company - tech
How Japan is using AI to prepare Tokyo residents for a Mount Fuji volcanic eruption

Mount Fuji hasn’t erupted since 1707. But for Volcanic Disaster Preparedness Day, Japanes

29 août 2025, 14:40:03 | Fast company - tech
Brides are asking brands for free wedding swag—and posting the hauls on TikTok

When an influencer gets married, it’s safe to assume much of the cost, from venue decor to personalized invitations, has been comped in exchange for content. Now brides with smaller, more modest f

29 août 2025, 12:20:09 | Fast company - tech
The secret history of how Intel ran the tech industry—until it didn’t

Welcome, and thanks for reading this issue of Fast Company’s Plugged In.

On August 22, President Donald Trump announced via Truth Social that the U.S. federal government had acq

29 août 2025, 12:20:09 | Fast company - tech
Why a rare blood cancer has become a testing ground for cancer drug innovation

Some of the most ambitious cancer science is happening in a disease few outside of oncology can name, and it’s revealing a future where cancer is no longer a death sentence.

Multiple mye

29 août 2025, 12:20:06 | Fast company - tech